Adaptive Biotechnologies Corp. Hits New 52-Week High at $21.64

Adaptive Biotechnologies Corp. has reached a significant milestone by hitting a new 52-week high of USD 21.64 on June 29, 2026. This achievement marks a remarkable performance for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, Adaptive Biotechnologies has demonstrated an impressive growth trajectory, with a staggering 513.18% increase in its stock price, significantly outperforming the S&P 500, which recorded a gain of 20.53% during the same period. The company's market capitalization stands at approximately USD 1,911 million, reflecting its position as a notable player in the small-cap sector. Despite its recent success, Adaptive Biotechnologies continues to face challenges, as indicated by its negative return on equity of -27.18% and a debt-to-equity ratio of -0.40. Additionally, the company does not currently offer a dividend, and its price-to-book ratio is 8.73. As Adaptive Biotechnologies Corp. continues to navigate the competitive landscape of the biotechnology sector, its recent stock performance highlights its potential in the market.